ESMO 2023: Highlights and analysis
ESMO 2023: Highlights and analysis
Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
CAR-T therapy and impact to cancer patient outcomes and experience of treatment
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer
Lung Cancer
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC
Where do we stand with mCRPC?
PARPi combinations to treat patients with mCRPC
Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer